CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone770-419-3355
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$262.84 million
Profitability
Miscellaneous
Employees1,100
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Cryolife (NYSE:CRY) Frequently Asked Questions
What is Cryolife's stock symbol?
Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."
How were Cryolife's earnings last quarter?
Cryolife Inc (NYSE:CRY) announced its quarterly earnings data on Tuesday, July, 30th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.08 by $0.03. The medical equipment provider had revenue of $71.14 million for the quarter, compared to analysts' expectations of $70.79 million. Cryolife had a return on equity of 3.85% and a net margin of 0.87%. The firm's quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 EPS. View Cryolife's Earnings History.
When is Cryolife's next earnings date?
What guidance has Cryolife issued on next quarter's earnings?
Cryolife updated its FY19 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $0.28-0.32 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.30. The company issued revenue guidance of $280-284 million, compared to the consensus revenue estimate of $282.20 million.
What price target have analysts set for CRY?
3 brokers have issued 12-month price objectives for Cryolife's stock. Their forecasts range from $29.65 to $35.00. On average, they expect Cryolife's share price to reach $32.2167 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for Cryolife.
What is the consensus analysts' recommendation for Cryolife?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cryolife.
What are Wall Street analysts saying about Cryolife stock?
Here are some recent quotes from research analysts about Cryolife stock:
- 1. According to Zacks Investment Research, "CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. " (4/23/2019)
- 2. Needham & Company LLC analysts commented, "CRY has undergone a transition into a higher growth company with two major acquisitions since 2015. We believe that it has a full pipeline including 13 new products and indications but we don’t expect these to begin to translate to stronger revenue growth until 2020. And 2019 appears to be a transition year from an earnings and margin perspective. Given all of this, and our belief that CRY shares are fairly valued, we initiate coverage with a Hold rating." (2/27/2019)
- 3. Northland Securities analysts commented, "We continue to be strongly bullish on CryoLife. Our thesis is predicated on a few simple things: 1) Our belief in the New product intros over the next few years. The stock currently trades at ~4x Sales, which is a discount to the 5.2x multiple for the broader space. For sure, the volatility in CryoLife stock will not be as much as other players in the space. But this is a steady eddy story." (1/17/2019)
Has Cryolife been receiving favorable news coverage?
News coverage about CRY stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cryolife earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Cryolife.
Who are some of Cryolife's key competitors?
Some companies that are related to Cryolife include Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Silk Road Medical (SILK), Luminex (LMNX), AtriCure (ATRC), Tactile Systems Technology (TCMD) and Orthofix Medical (OFIX).
What other stocks do shareholders of Cryolife own?
Who are Cryolife's key executives?
Cryolife's management team includes the folowing people:
- Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 52)
- Mr. David Ashley Lee CPA, CPA, Exec. VP, COO & CFO (Age 54)
- Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 62)
- Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 54)
- Ms. Amy D. Horton CPA, CPA, VP & Chief Accounting Officer (Age 49)
Who are Cryolife's major shareholders?
Cryolife's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.30%), Vanguard Group Inc. (6.07%), Morgan Stanley (4.38%), Northern Trust Corp (3.15%), Wasatch Advisors Inc. (1.65%) and William Blair Investment Management LLC (1.39%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, David C Gale, Harvey Morgan, James Benson, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Institutional Ownership Trends for Cryolife.
Which major investors are selling Cryolife stock?
CRY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Invesco Ltd., First Trust Advisors LP, Russell Investments Group Ltd., William Blair Investment Management LLC, Royal Bank of Canada and Parametric Portfolio Associates LLC. Company insiders that have sold Cryolife company stock in the last year include Amy Horton, David Ashley Lee, James P Mackin, Jean F Holloway, Ronald D Mccall and Scott B Capps. View Insider Buying and Selling for Cryolife.
Which major investors are buying Cryolife stock?
CRY stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Point72 Asset Management L.P., Wasatch Advisors Inc., Monarch Partners Asset Management LLC, Morgan Stanley, Vanguard Group Inc., Marshall Wace LLP and Hodges Capital Management Inc.. View Insider Buying and Selling for Cryolife.
How do I buy shares of Cryolife?
Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cryolife's stock price today?
One share of CRY stock can currently be purchased for approximately $29.34.
How big of a company is Cryolife?
Cryolife has a market capitalization of $1.10 billion and generates $262.84 million in revenue each year. The medical equipment provider earns $-2,840,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. Cryolife employs 1,100 workers across the globe.View Additional Information About Cryolife.
What is Cryolife's official website?
How can I contact Cryolife?
Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected]
MarketBeat Community Rating for Cryolife (NYSE CRY)
MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
